Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 16/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.40 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880733 | 0.89 | ADORA2A (0.45) | ADORA2AADORA1ADORA2BTGFBR1 | |
| SCHEMBL22579271 | 0.89 | ADORA2A (0.45) | ADORA2AADORA1ADORA2BTGFBR1 | |
| SCHEMBL22551897 | 0.89 | ADORA2A (0.53) | ADORA2AADORA1ADORA2BTGFBR1TGFBR2 | |
| SCHEMBL30880786 | 0.89 | ADORA2A (0.53) | ADORA2AADORA1ADORA2BTGFBR1TGFBR2 | |
| SCHEMBL22551808 | 0.87 | ADORA2A (0.44) | ADORA2AADORA1ADORA2BTGFBR1 | |
| SCHEMBL30880767 | 0.87 | ADORA2A (0.44) | ADORA2AADORA1ADORA2BTGFBR1 | |
| SCHEMBL23774592 | 0.85 | ADORA2A (0.46) | ADORA2AADORA1ADORA2BTGFBR1TGFBR2 | |
| SCHEMBL23774605 | 0.83 | ADORA2A (0.39) | ADORA2AADORA1ADORA2BTGFBR1 | |
| SCHEMBL22552059 | 0.82 | TGFBR1 (0.45) | ADORA2AADORA1ADORA2BTGFBR1TGFBR2 | |
| SCHEMBL30880837 | 0.82 | TGFBR1 (0.45) | ADORA2AADORA1ADORA2BTGFBR1TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181092-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885 |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.